Amylin Pharmaceuticals Inc. (AMLN)

[SeriousMoney]

Toby's latest on AMLN 12/1/05

AMYLIN (AMLN): A terrific performer and a big long-term winning company -- does this stock have legs!

* Recent Trends: Mostly up -- a very solid chart with recent gains being consolidated on somewhat lower volume. The Big Pharma analysts and mutual funds are getting into the stock and a good deal of the recent rise is from this flow of funds.

* Upside Catalysts: There are two major upside catalysts in the next six months. The first is sales data for Byetta and Symlin (another recently approved drug), and the second is more trial data and FDA application dates for the long-lasting version of Byetta. One wild card is an outright purchase of the company by partner Eli Lilly (LLY), something increasingly remote as the stock price increases.

* Downside Catalysts: Any problem with Byetta is a big problem for the stock. Also, the company could buy another firm or additional licensing rights, but it's a cash-rich company ($500 million in the bank) and might not need to issue shares for a small deal.

http://www.changewave.com/biotech/